Thank You for Your Interest
in Referring Study Candidates to a
Clinical Study Site in Your Area.
A Rebiotix clinical representative will contact you shortly
To provide additional information about your interest in C. difficile and other microbiome clinical research
Thank you for your interest in referring recurrent C. difficile infection patients to a clinical study site in your area. To help us better understand your interest, send a message to study sponsor Rebiotix by providing the following information:
The PUNCH CD3 clinical research study is a Phase 3 Study to evaluate Rebiotix RBX2660 (microbiota suspension) for the prevention of recurrent Clostridium difficile infection (CDI).
PUNCH CD3 is currently active and enrolling at several locations across the United States and Canada. This is the fourth clinical study evaluating RBX2660 for recurrent CDI and all studies have been filed with FDA as part of an investigational new drug application.
Study treatment consists of a single blinded enema of RBX2660 or placebo according to the 2 to 1 randomization assignment. Study patients who are deemed treatment failures following the blinded treatment may elect to receive an unblinded (active) RBX2660 study drug treatment.
Primary efficacy endpoint is the recurrence of CDI within 8 weeks of blinded treatment. Secondary safety and efficacy endpoints are evaluated through 6 months.
Lead candidate RBX2660 is a standardized, stabilized microbiota-based drug created from a broad consortium of spore and non-spore forming microbes. RBX2660 is prepared from thoroughly screened healthy human donors and is administered by ready-to-use enema.
RBX2660 has previously been studied in three Phase 2 regulated clinical studies and has been granted Fast Track status, Orphan Drug and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent CDI.
Further information is available:
About the Sponsor
Rebiotix Inc. is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.
2660 Patton Road
Roseville, MN 55113